Charme Capital Buys 70% of Tema Sinergie’s Clinical Solutions

Charme Capital Partners sgr has won the auction for control of Tema Sinergie, a company that develops highly specialized clinical solutions and technology systems, based on an enterprise value of 200 million euros. Tema Sinergie’s financial advisor was Mediobanca. The auction had also seen interest from Hourglass Private Equity, Ardian, Apax Partners, and Agic Capital.

In detail, the Charme IV fund will acquire 70 percent of Tema Sinergie’s capital, with the founders retaining the remaining 30 percent. Until now, the capital was controlled by Luciano and Stefano Piancastelli, chairman and CEO respectively (with 25 percent and 15 percent), Aurelio Romualdi (30 percent), Amedeo Laghi (20 percent), and Andrea Peroni (10 percent).

The company ended 2021 with 51.9 million euros in net revenues, Ebitda of 9 million, and net cash of 2.1 million. Tema Sinergie’s business plan for the next three years envisages 200 new hires, thus doubling the current production force (the company now has a team of 200 people, including 60 engineers, physicists, and computer scientists) and an investment of about 15 million euros to triple the production site in Faenza.

Read more on the subject and find the latest financial news of the day with the Born2Invest mobile app.

Charme Capital also invested in Igenomix

For the fourth fund of the sgr led by Matteo di Montezemolo, which closed the collection with 800 million euros in commitments, this is the fifth investment. Last March, the fund announced the acquisition of control of Prism Healthcare, a leading British provider of end-to-end healthcare equipment and services. The previous investor, Limerston Capital, retained a stake in the capital, as did management.

Last February, on the other hand, Charme together with the Miura Capital fund announced the acquisition of Spain’s Indiba, a world leader in radiofrequency solutions for the physiotherapy, aesthetic, and veterinary markets. The seller had been Magnum Capital for about 150 million euros.

In July 2021 Charme had again reinvested in Igenomix, a leading Spanish biotechnology group with an innovative portfolio of products focused on prenatal genetic diagnostics. Indeed, Vitrolife, a Stockholm-listed Swedish assisted reproduction company, acquired Igenomix from EQT, then a majority shareholder, and from Charme, which had previously sold to EQT while retaining a minority stake. Both EQT and Charme reinvested in the new group.

Finally, in June 2021, Charme announced the acquisition of control of Bianalisi spa diagnostic centers, one of Italy’s leading players in clinical testing and specialty diagnostics, and the first closing of the Charme IV fund at 500 million.

__

(Featured image by PublicDomainPictures via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Be Beez, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.